Shook & Fletcher Insulation Co. Asbestos Trust Claims

Shook & Fletcher Asbestos Trust Facts

Bankruptcy and Trust History

CRMC’s official Trust page states that the Shook & Fletcher Asbestos Settlement Trust became effective on December 11, 2002 pursuant to the Second Amended Plan of Reorganization of Shook & Fletcher Insulation Co., Inc. The Trust was formed to pay valid Trust Claims under its Claims Resolution Procedures.

The CRP identifies April 8, 2002 as the Chapter 11 Petition Date and the U.S. Bankruptcy Court for the Northern District of Alabama as the Bankruptcy Court. A Delaware court decision involving the Trust independently records that Shook & Fletcher filed Chapter 11 on April 8, 2002 and that its reorganization created a settlement trust for pending and future asbestos claims.

Historical court records discuss anticipated insurance and debtor contributions to fund the Trust. Those historical funding figures are not represented here as current assets.

Who May Qualify for a Shook & Fletcher Claim?

The CRP recognizes four compensable Disease Categories: Mesothelioma, Lung Cancer, Other Cancer and Non-Malignant Asbestos-Related Disease. Each category has medical and exposure requirements.

Current claim instructions require a completed claim form, a medical diagnosis of a compensable disease, and evidence of Shook & Fletcher exposure with the beginning and ending dates of that exposure. Additional estate, death or lawsuit-dismissal documentation may be required depending on the claim.

Claims can involve asbestos-containing products distributed, sold, installed, stored, transported, removed or otherwise handled by Shook & Fletcher, as well as qualifying asbestos-related services or operations for which the company bears legal responsibility.

Disease Categories and Matrix Values

The published CRP uses location-specific Matrix Values, rather than one national Scheduled Value. The base matrix published in the CRP is:

Important: the CRP states that these Matrix Values are subject to inflation increases beginning in 2008, with the Trustee authorized to set increases with the required consent. The figures above are therefore identified as the published base matrix, not represented as unadjusted current 2026 values.

Expedited Review offers the applicable current Matrix Value for the Disease Category and Location of Exposure, multiplied by the then-applicable Payment Percentage.

Need help now? Call 800.291.0963
Live chat available 24/7, 365 days a year.
Submit Your Case

Current 58% Payment Percentage

An official Shook Trust notice dated May 30, 2025 increased the Payment Percentage from 50% to 58%, effective immediately. The notice states that claimants will receive 58% of their approved claim values.

The notice also states that claimants who previously received 50% of approved claim value would receive a supplemental payment equal to 8% of approved claim value, subject to the CRP rule that the Trust not make distributions of less than $175 per claimant.

The Trustee may adjust the Payment Percentage in the future under the CRP. The 58% rate is the latest official Shook-specific payment notice located in CRMC’s current materials.

Mathematical illustration only — not a guaranteed payment. Using the CRP’s historical base Matrix solely to demonstrate the percentage calculation, a $22,000 base mesothelioma Matrix Value × 58% = $12,760. Because the CRP provides for inflation adjustments to Matrix Values, this is not presented as a current claim offer or guaranteed payment.

Claim Filing and Review Procedures

The Trust uses a FIFO Processing Queue for CRP-valued claims. Expedited Review is intended for claims that can readily satisfy the presumptive medical and exposure requirements. A qualifying claim is offered the applicable Matrix Value for its Disease Category and Location of Exposure, multiplied by the Payment Percentage.

Individual Review is available in circumstances described by the CRP, including claims that do not satisfy all presumptive criteria but may still be valid in the tort system, Extraordinary Claims and derivative claims. The published CRP states an historical $100 Individual Review fee, but current filing-fee policies can change and should be checked in CRMC’s current document library before filing.

The Trust also maintains ADR procedures, a claims-audit program, second-disease rules and evidentiary requirements. CRMC currently provides proof-of-claim forms, instructions, approved-site information and eClaims access.

Medical and Exposure Requirements

For Mesothelioma, the published CRP requires a report from a Board-Certified Pathologist diagnosing malignant mesothelioma plus evidence of Shook & Fletcher Exposure before December 31, 1985.

Lung Cancer requires a primary lung-cancer diagnosis, physician causation evidence, supporting asbestos-related nonmalignant findings and a cumulative six months of Shook & Fletcher Exposure before December 31, 1985. Other Cancer has comparable six-month exposure requirements and is limited by the CRP to specified primary cancers.

Non-Malignant claims require qualifying medical evidence, six months of Shook & Fletcher Exposure before December 31, 1985 and five years of cumulative occupational asbestos exposure. Current claim instructions require exposure dates and supporting evidence with the proof of claim.

2025–2026 Claim Procedure Updates

The Trust remains operational. CRMC’s official Trust page identifies CRMC as the claims processor and directs claimants to the current document library and eClaims system.

On May 21, 2026, the Trustee, with the consent of the Trust Advisory Committee and Futures Representative, amended CRP section 5.4 governing Derivative Claims. The amendment is effective immediately and applies to pending and future claims.

Under the amended rule, a claimant alleging secondary exposure through an occupationally exposed person—such as a family member—must elect Individual Review and pay the applicable IR Fee. The claimant must establish a compensable disease, show that the occupationally exposed person would satisfy the applicable direct-exposure requirements, establish contemporaneous secondary exposure and show that the secondary exposure caused the claimed disease.

For secondary-exposure diseases other than mesothelioma, the amendment imposes additional duration requirements. The Trust’s current procedures should therefore be reviewed rather than relying solely on the older 2011 CRP text.

Confirmed Primary Sources for Trust Facts

No law-firm or lead-generation website was used as factual authority for this page. Primary and official Trust materials reviewed include:

• CRMC’s official Shook & Fletcher Asbestos Settlement Trust page.
• Official Shook & Fletcher Trust document library.
• Official Claims Resolution Procedures.
• Official May 1, 2024 Proof of Claim filing instructions.
• Official May 30, 2025 Payment Percentage Increase notice.
• Official CRMC announcements, including the May 21, 2026 derivative-claim amendment.

A sufficiently current public audited financial report establishing current Trust assets, cumulative claims paid and lifetime dollars paid was not located in the official Shook materials reviewed, so those statistics are omitted rather than inferred.

Get Help Reviewing a Shook & Fletcher Asbestos Claim

Call 800.291.0963

Live chat is available 24/7, 365 days a year.

Submit Your Case

Prior asbestos exposure does not automatically establish eligibility for a Shook & Fletcher trust claim or asbestos lawsuit. Eligibility depends on medical and exposure evidence, current Trust procedures, filing requirements and individual circumstances. Compensation is not guaranteed.